Dongkoo Bio&Pharma Q1 2026 Operating Profit of KRW 1.8B… Net Loss and Higher Debt Ratio

Q1 2026 consolidated revenue KRW 58.06B (vs 58.68B YoY, -1.0%), operating profit KRW 1.81B (vs 2.33B, -22.3%), net loss KRW 0.58B (vs net loss 0.72B)
Separate: revenue KRW 57.56B, operating profit KRW 2.14B, net loss KRW 0.67B
Debt ratio consolidated 128.5% (FY2025 end: 121.1%), separate 124.3% (117.4%)
Dermatology prescription market share 7.6% (2025, slightly down from 7.9%), urology 4.5% (up from 4.3%)
R&D expense KRW 4.71B (8.2% of revenue), up 1.7% YoY
Outstanding exchangeable bonds KRW 8.68B (conversion price KRW 6,103), with put option (exercisable from Mar 31, 2027)
Pending administrative litigation regarding GMP cancellation (injunction granted, no business impact)
Pending litigation over choline alfoscerate clinical reassessment and reimbursement clawback
Prior year (FY2025) cash dividend of KRW 3.25B (KRW 120 per share) approved at AGM on Mar 31, 2026